The following EPHB4 gene sequences were retrieved from the NCBI Reference Sequence Database (RefSeq). These sequences represent the protein coding region of the EPHB4 gene which is encoded by the open reading frame (ORF) sequence. ORF sequences can be delivered in our standard vector, pcDNA3.1+/C-(K)DYK or the vector of your choice as an expression/transfection-ready ORF clone. Not the clone you want? Click here to find your clone.
||Documents for ORF clone product in dufault vector
||ORF Nucleotide Sequence (Length: 2964bp)
||pcDNA3.1+/C-(K)DYK or customized vector
|Tag on pcDNA3.1+/C-(K)DYK
||C terminal DYKDDDDK tags
|ORF Insert Method
||CloneEZ® Seamless cloning technology
||Homo sapiens (human)
||ephrin type-B receptor 4 precursor
||REVIEWED REFSEQ: This record has been curated by NCBI staff. The
reference sequence was derived from CB962032.1, BC052804.1 and
On Nov 16, 2004 this sequence version replaced gi:32528300.
Summary: Ephrin receptors and their ligands, the ephrins, mediate
numerous developmental processes, particularly in the nervous
system. Based on their structures and sequence relationships,
ephrins are divided into the ephrin-A (EFNA) class, which are
anchored to the membrane by a glycosylphosphatidylinositol linkage,
and the ephrin-B (EFNB) class, which are transmembrane proteins.
The Eph family of receptors are divided into 2 groups based on the
similarity of their extracellular domain sequences and their
affinities for binding ephrin-A and ephrin-B ligands. Ephrin
receptors make up the largest subgroup of the receptor tyrosine
kinase (RTK) family. The protein encoded by this gene binds to
ephrin-B2 and plays an essential role in vascular development.
[provided by RefSeq, Jul 2008].
Publication Note: This RefSeq record includes a subset of the
publications that are available for this gene. Please see the Gene
record to access additional publications.
Transcript exon combination :: BC052804.1, U07695.1 [ECO:0000332]
RNAseq introns :: mixed/partial sample support
COMPLETENESS: complete on the 3' end.